M.S., Vice President of Business Development, TOMA Biosciences
With more than 18 years of experience, Greg leads business development and commercial operations. He has been instrumental in shaping the commercial model and raising capital since TOMA’s founding. His passion for finding new oncology treatment options for patients began while part of the proteomics team at Myriad Genetics a cancer diagnostics pioneer. In addition to finance, sales and marketing experience, Greg gained deep oncology experience while leading teams through the evaluation process of new oncology therapeutic development programs at Genentech (Roche), and advising global pharmaceutical clients as a consultant at IMS Consulting Group and in Ernst & Young’s life science practice. He graduated from the University of Utah in Human Biology and received a Masters of Science in Business Management from the Stanford Graduate School of Business as a Sloan Fellow with an emphasis in new venture formation.
Navigating Through FFPE to Identify Changes in Tumor DNA
Clinical Dx Showcase: A Robust Targeted Sequencing Approach for Low Input and Variable Quality DNA from Clinical Samples